In another real-life analysis, this time with Nivolumab, another anti-PD-L1, which included a considerable number of patients, 409 patients with asymptomatic brain disease, Nivolumab monotherapy reported response rates of around 17% with a median OS of 8.6 months and median PFS was 3.0 months (39). This evidence concerns the gene CD274 and brain disorder.